Physician profile

Kierann E Toth

Family Medicine · Fort Collins, CO

NPI 1346539665

$281.16

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$55.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $117.16 2022-2024
Amgen INC. $34.48 2020
Janssen Pharmaceuticals, INC $25.75 2019
Abbott Laboratories $21.49 2024 Freestyle Libre 3
Edwards Lifesciences Corporation $19.50 2019
Radius Health, INC. $18.59 2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $16.14 2019
Regeneron Healthcare Solutions, INC. $14.76 2019
Amarin Pharma, INC. $13.29 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kierann E Toth

$281.16

in general payments reported 2019-2025

Years
2019-2024
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/1284401/kierann-e-toth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.